IPHA biotech catalysts & pipeline

INNATE PHARMA SA · Data as of 2026-09-08

Upcoming catalysts

2026

Clinical data are expected to be presented in 2026.

H2 2026

PACIFIC-9 Phase 3 trial, which includes monalizumab and is led by AstraZeneca, continues to advance toward a planned H2 2026 data readout

by year-end

Preliminary data are expected by year-end and will include data from 76 patients, guiding Phase 1 dose optimization in selected tumor types.